PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1

SIMPLE SUMMARY: Many kinase inhibitors have been tested as potential alternatives for the treatment of castration-resistant prostate cancers. However, none of these clinical trials led to drug approval despite interesting responses. Our study reveals that genes involved in drug metabolism and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Matheux, Alice, Gassiot, Matthieu, Fromont, Gaëlle, Leenhardt, Fanny, Boulahtouf, Abdelhay, Fabbrizio, Eric, Marchive, Candice, Garcin, Aurélie, Agherbi, Hanane, Combès, Eve, Evrard, Alexandre, Houédé, Nadine, Balaguer, Patrick, Gongora, Céline, Mbatchi, Litaty C., Pourquier, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305337/
https://www.ncbi.nlm.nih.gov/pubmed/34298852
http://dx.doi.org/10.3390/cancers13143635

Ejemplares similares

Ejemplares similares